Collegium Pharmaceutical, Inc. $COLL Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,365 shares of the specialty pharmaceutical company’s stock after buying an additional 15,475 shares during the quarter. Pacer Advisors Inc. owned about 0.79% of Collegium Pharmaceutical worth $8,478,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its stake in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after acquiring an additional 538,337 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical by 65.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after purchasing an additional 518,721 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares during the period. Two Sigma Investments LP increased its holdings in shares of Collegium Pharmaceutical by 897.2% during the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after purchasing an additional 242,310 shares during the period. Finally, Qube Research & Technologies Ltd raised its stake in shares of Collegium Pharmaceutical by 237.9% during the third quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock valued at $11,216,000 after purchasing an additional 225,679 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on COLL shares. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $35.73 on Wednesday. The company has a 50-day moving average of $34.91 and a 200-day moving average of $37.32. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 17.51 and a beta of 0.73. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical, Inc. has a twelve month low of $29.70 and a twelve month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.49 EPS. Analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.